Real-world prevalence of hepatitis B virus reactivation in cancer patients in Taiwan.

Chi-Hua ChenHui-Hsia HsiehTien-Yuan Wu

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2020)

Our findings indicate that cancer patients receiving prophylactic antiviral drugs remain at risk of hepatitis B virus reactivation during chemotherapy. Therefore, the hepatitis B virus screen and chemotherapy control system was established in 2017 to reduce the risk of hepatitis B virus reactivation and improve patient safety.

Keyphrases

hepatitis b virus
patient safety
liver failure
quality improvement
locally advanced
risk factors
papillary thyroid
high throughput
radiation therapy
single cell